Hospital Universitario De Cabuenes — Clinical Trial Site

50 Registered trials

19 Currently recruiting

Organisation

Hospital Universitario De Cabuenes

Location

Gijon, Spain

Identifier

ORG-100043970

Address

Calle Prados 395, Cabuenes, 33394, Spain

Departments

#2310:servicio de neurología
CARDILOGY
Cardiology
Digestive
Digestive system
Digestivo
ES10019: Hematología
Gastroenterology
Hematology
Hematology Service
Hospital de Cabueñes, Gijón
Nefrology
Oncology
Servicio de Aparato Digestivo
Servicio de Cardiologia
Servicio de Endocrinologia
Servicio de Hematologia
Surgery
Unidad de Enfermedad Inflamatoria Intestinal

Clinical trials at this site (50)

Search interface

A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Recruiting

2023-507809-34-00 Relapsed or Refractory Systemic Light Chain Amyloidosis 9 2024-08-07
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI (DEBATE) Recruiting

2023-504340-34-01 Coronary artery disease 6 2024-01-11
A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni… Ended

2024-513970-23-00 Previously Untreated Chronic Lymphocytic Leukemia 4 2025-02-27
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended

2022-501396-62-00 Relapsed Refractory Multiple Myeloma 5 2023-12-12
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 4 2023-10-31
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended

2023-503441-55-00 Relapsed/Refractory Multiple Myeloma 4 2021-10-14
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended

2022-503072-84-00 stage IIIa cardiac AL amyloidosis 5 2021-02-13
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Stage IIIb cardiac AL amyloidosis 5 2021-02-13
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended

2023-506877-37-00 Relapsed/Refractory Multiple Myeloma 5 2020-09-28
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Multiple Myeloma 5 2018-12-24
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e… Ended

2024-516130-35-00 Multiple myeloma 4 2024-09-26
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended

2024-519633-35-00 Resectable pancreatic adenocarcinoma with risk factors 6 2021-10-25